Browse All Medication Resources

Features Resources

MS and Related disorders: Approach to JCV testing with natalizumab biosimilar: a UK consensus statement

By Aimee.Milne | May 22, 2025

Using DMT’s in MS: ABN 2024 guidance

By Aimee.Milne | March 19, 2025

Barts Health: Guidelines for the use of Ublituximab 2025

By Aimee.Milne | March 19, 2025
Search
All
  • All
  • Medication

MS Journal: A comparison of JC virus assay performance provided with originator and biosimilar natalizumab

By Aimee.Milne | June 17, 2025
Muraro_AHSCT_NatureReveiws_2025

Nature Reviews: Autologous haematopoietic stem cell transplantation for treatment of MS and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT

By Aimee.Milne | June 10, 2025
Approach to JCV testing with natalizumab biosimilar - a UK consensus statement

MS and Related disorders: Approach to JCV testing with natalizumab biosimilar: a UK consensus statement

By Aimee.Milne | May 22, 2025
Using DMTs in MS- ABN 2024 guidance

Using DMT’s in MS: ABN 2024 guidance

By Aimee.Milne | March 19, 2025
2025 01 Guidelines for the use of Ublituximab (1)

Barts Health: Guidelines for the use of Ublituximab 2025

By Aimee.Milne | March 19, 2025
Teriflunomide protocol - Cambridge - November 2021

Teriflunomide protocol Cambridge November 2021

By Transforming MS For All | August 7, 2023

Siponimod protocol Cambridge February 2022

By Transforming MS For All | August 7, 2023

Ponesimod protocol Cambridge August 2022

By Transforming MS For All | August 7, 2023

Ofatumumab protocol Cambridge November 2021

By Transforming MS For All | August 7, 2023

Ocrelizumab protocol Cambridge November 2021

By Transforming MS For All | August 7, 2023